Please wait a minute...
J Zhejiang Univ (Med Sci)  2020, Vol. 49 Issue (3): 340-346    DOI: 10.3785/j.issn.1008-9292.2020.05.02
    
Coagulation dysfunction in COVID-19
XU Yiming(),LYU Dandan,YING Kejing*()
Department of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
Download: HTML( 8 )   PDF(1035KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

In addition to common clinical features, patients with coronavirus disease 2019 (COVID-19) have varying degree of coagulation dysfunction with the risk of thrombosis and/or bleeding. COVID-19 related coagulation dysfunction is a dynamic process, which may be accompanied by the formation of disseminated intravascular coagulation and is related to the severity of the disease. The imbalance of the body's immune and inflammatory response caused by coronavirus infection is an important cause of coagulation dysfunction. Dynamic monitoring as well as early prevention and treatment are of great significance for improving the prognosis of patients. This article reviews the research progress of COVID-19 related coagulation dysfunction, to provide reference for clinical research and management.



Key wordsCoronavirus disease 2019      Severe acute respiratory syndrome coronavirus 2      Novel coronavirus pneumonia      Coagulation dysfunction      Inflammation      Immunity     
Received: 13 April 2020      Published: 10 June 2020
CLC:  R512.99  
Corresponding Authors: YING Kejing     E-mail: 21918273@zju.edu.cn;3197061@zju.edu.cn
Cite this article:

XU Yiming,LYU Dandan,YING Kejing. Coagulation dysfunction in COVID-19. J Zhejiang Univ (Med Sci), 2020, 49(3): 340-346.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.05.02     OR     http://www.zjujournals.com/med/Y2020/V49/I3/340


2019冠状病毒病(COVID-19)患者出凝血功能障碍的研究进展

2019冠状病毒病(COVID-19)患者除常见临床特征之外,还有不同程度的出凝血功能障碍,存在合并血栓和/或出血的风险。COVID-19相关的出凝血功能障碍多为动态过程,可伴有弥散性血管内凝血的形成,与疾病危重程度相关。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染后所导致的机体免疫炎症反应失衡是患者凝血功能紊乱的重要原因,动态监测、早期防治对于改善患者预后有重大意义。本文就COVID-19患者出凝血功能障碍相关研究进展作一综述,以期为临床研究及决策提供参考。


关键词: 2019冠状病毒病,  严重急性呼吸综合征冠状病毒2,  新型冠状病毒肺炎,  出凝血功能障碍,  炎症,  免疫 
[1]   HUANG C , WANG Y , LI X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395 (10223): 497- 506
doi: 10.1016/S0140-6736(20)30183-5
[2]   WANG D , HU B , HU C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323 (11): 1061- 1069
doi: 10.1001/jama.2020.1585
[3]   GUAN W J , NI Z Y , HU Y et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382 1708- 1720
doi: 10.1056/NEJMoa2002032
[4]   ARACHCHILLAGE D , LAFFAN M . Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J]. J Thromb Haemost, 2020, 18 (5): 1233- 1234
doi: 10.1111/jth.14820
[5]   刘茜, 王荣帅, 屈国强 et al. 新型冠状病毒肺炎死亡尸体系统解剖大体观察报告[J]. 法医学杂志, 2020, 36 (1): 21- 23
LIU Qian , WANG Rongshuai , QU Guoqiang et al. Gross examination report of a COVID-19 death autopsy[J]. Journal of Forensic Medicine, 2020, 36 (1): 21- 23
doi: 10.12116/j.issn.1004-5619.2020.01.005
[6]   XU Z , SHI L , WANG Y et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8 (4): 420- 422
doi: 10.1016/S2213-2600(20)30076-X
[7]   CHEN N , ZHOU M , DONG X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:a descriptive study[J]. Lancet, 2020, 395 (10223): 507- 513
doi: 10.1016/S0140-6736(20)30211-7
[8]   MAO L, WANG M, CHEN S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study[J/OL]. medRxiv, 2020. DOI: 2020.2002.2022.20026500.
[9]   FOLEY J H , CONWAY E M . Cross talk pathways between coagulation and inflammation[J]. Circ Res, 2016, 118 (9): 1392- 1408
doi: 10.1161/CIRCRESAHA.116.306853
[10]   IBA T , LEVY J H . Inflammation and thrombosis:roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis[J]. J Thromb Haemost, 2018, 16 (2): 231- 241
doi: 10.1111/jth.13911
[11]   KAWAI T , AKIRA S . Signaling to NF-κB by Toll-like receptors[J]. Trends Mol Med, 2007, 13 (11): 460- 469
doi: 10.1016/j.molmed.2007.09.002
[12]   YANG X , LI L , LIU J et al. Extracellular histones induce tissue factor expression in vascular endothelial cells via TLR and activation of NF-κB and AP-1[J]. Thromb Res, 2016, 137 211- 218
doi: 10.1016/j.thromres.2015.10.012
[13]   SEMERARO F , AMMOLLO C T , MORRISSEY J H et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms:involvement of platelet TLR2 and TLR4[J]. Blood, 2011, 118 (7): 1952- 1961
doi: 10.1182/blood-2011-03-343061
[14]   KERAGALA C B , DRAXLER D F , MCQUILTEN Z K et al. Haemostasis and innate immunity-a complementary relationship:A review of the intricate relationship between coagulation and complement pathways[J]. Br J Haematol, 2018, 180 (6): 782- 798
doi: 10.1111/bjh.15062
[15]   ZHOU P , YANG X L , WANG X G et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579 (7798): 270- 273
doi: 10.1038/s41586-020-2012-7
[16]   WRAPP D , WANG N , CORBETT K S et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020, 367 (6483): 1260- 1263
doi: 10.1126/science.abb2507
[17]   KUBA K , IMAI Y , OHTO-NAKANISHI T et al. Trilogy of ACE2:a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters[J]. Pharmacol Ther, 2010, 128 (1): 119- 128
doi: 10.1016/j.pharmthera.2010.06.003
[18]   GLOWACKA I , BERTRAM S , HERZOG P et al. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63[J]. J Virol, 2010, 84 (2): 1198- 1205
doi: 10.1128/JVI.01248-09
[19]   WANG M, HAO H, LEEPER N J, et al. Thrombotic regulation from the endothelial cell perspectives[J/OL]. Arterioscler Thromb Vasc Biol, 2018, 38(6): e90-e95. DOI: 10.1161/ATVBAHA.118.310367.
[20]   SODHI C P , WOHLFORD-LENANE C , YAMAGUCHI Y et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration[J]. Am J Physiol Lung Cell Mol Physiol, 2018, 314 (1): L17- L31
doi: 10.1152/ajplung.00498.2016
[21]   SODHI C P , NGUYEN J , YAMAGUCHI Y et al. A dynamic variation of pulmonary ACE2 is required to modulate neutrophilic inflammation in response to pseudomonas aeruginosa lung infection in mice[J]. J Immunol, 2019, 203 (11): 3000- 3012
doi: 10.4049/jimmunol.1900579
[22]   VAN DER POLL T , VAN DE VEERDONK F L , SCICLUNA B P et al. The immunopathology of sepsis and potential therapeutic targets[J]. Nat Rev Immunol, 2017, 17 (7): 407- 420
doi: 10.1038/nri.2017.36
[23]   LEVI M , VAN DER POLL T , BVLLER H R . Bidirectional relation between inflammation and coagulation[J]. Circulation, 2004, 109 (22): 2698- 2704
doi: 10.1161/01.CIR.0000131660.51520.9A
[24]   MOORE K L , ESMON C T , ESMON N L . Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture[J]. Blood, 1989, 73 (1): 159- 165
doi: 10.1182/blood.V73.1.159.159
[25]   LEFRAN?AIS E , ORTIZ-MU?OZ G , CAUDRILLIER A et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors[J]. Nature, 2017, 544 (7648): 105- 109
doi: 10.1038/nature21706
[26]   VARJú I , KOLEV K . Networks that stop the flow:A fresh look at fibrin and neutrophil extracellular traps[J]. Thromb Res, 2019, 182 1- 11
doi: 10.1016/j.thromres.2019.08.003
[27]   ENGELMANN B , MASSBERG S . Thrombosis as an intravascular effector of innate immunity[J]. Nat Rev Immunol, 2013, 13 (1): 34- 45
doi: 10.1038/nri3345
[28]   POTZE W , PORTE R J , LISMAN T . Management of coagulation abnormalities in liver disease[J]. Expert Rev Gastroenterol Hepatol, 2015, 9 (1): 103- 114
doi: 10.1586/17474124.2014.934673
[29]   芦泽源, 王锋, 汪年松 . 抗凝血酶Ⅲ与肾损伤的相关研究进展[J]. 中国中西医结合肾病杂志, 2015, 16 (6): 549- 551
LU Zeyuan , WANG Feng , WANG Niansong . Research progress on antithrombin Ⅲ and kidney damage[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2015, 16 (6): 549- 551
[30]   CHIOU H E , LIU C L , BUTTREY M J et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome:experience in two medical centers[J]. Chest, 2005, 128 (1): 263- 272
doi: 10.1378/chest.128.1.263
[31]   张瑞祺 . α干扰素的血液学不良反应及处理[J]. 肝脏, 2004, S1 36- 39
ZHANG Ruiqi . Hematological side effects and management of αinterferon[J]. Chinese Hepatology, 2004, S1 36- 39
[32]   DUSHEIKO G . Side effects of alpha interferon in chronic hepatitis C[J]. Hepatology, 1997, 26 (3 Suppl 1): 112S- 121S
doi: 10.1002/hep.510260720
[33]   THOMAS J , KOSTOUSOV V , TERUYA J . Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation[J]. Semin Thromb Hemost, 2018, 44 (1): 20- 29
doi: 10.1055/s-0037-1606179
[34]   MURPHY D A , HOCKINGS L E , ANDREWS R K et al. Extracorporeal membrane oxygenation-hemostatic complications[J]. Transfus Med Rev, 2015, 29 (2): 90- 101
doi: 10.1016/j.tmrv.2014.12.001
[35]   ZHOU F , YU T , DU R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study[J]. Lancet, 2020, 395 (10229): 1054- 1062
doi: 10.1016/S0140-6736(20)30566-3
[36]   中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组 et al. 新型冠状病毒肺炎相关静脉血栓栓塞症防治建议(试行)[J]. 中华医学杂志, 2020, 100 (11): 808- 813
Pulmonary Embolism and Pulmonary Vascular Disease Group , Chinese Medical Association; Working Committee of Pulmonary Embolism and Pulmonary Vascular Disease , Chinese Medical Doctor Association; National Collaborative Group for Prevention and Treatment of Pulmonary Embolism and Pulmonary Vascular disease et al. Recommendations for prevention and treatment of venous thromboembolism associated with COVID-19(trial)[J]. National Medical Journal of China, 2020, 100 (11): 808- 813
doi: 10.3760/cma.j.cn112137-20200209-00227
[37]   中国老年医学学会, 国家老年疾病临床医学研究中心(解放军总医院), 解放军老年医学专业委员会 . 感染诱发的老年多器官功能障碍综合征诊断与治疗中国指南2019[J]. 中华老年多器官疾病杂志, 2019, 18 (11): 801- 838
Chinese Society of Geriatrics , National Clinical Medical Research Center for Geriatrics (PLA general hospital) , PLA Geriatrics Professional Committee . 2019 China guidelines for diagnosis and treatment of infection-induced multiorgan dysfunction syndrome in the elderly[J]. Chinese Journal of Multiple Organ Diseases in the Elderly, 2019, 18 (11): 801- 838
doi: 10.11915/j.issn.1671-5403.2019.11.174
[38]   中华医学会血液学分会血栓与止血学组 . 弥散性血管内凝血诊断中国专家共识(2017年版)[J]. 中华血液学杂志, 2017, 38 (5): 361- 363
Thrombosis and Hemostasis Group, Hematology Society of Chinese Medical Association . Consensus of Chinese experts on diagnosis of disseminated intravascular coagulation (version 2017)[J]. Chinese Journal of Hematology, 2017, 38 (5): 361- 363
doi: 10.3760/cma.j.issn.0253-2727.2017.05.001
[39]   高倩, 甄凯元, 刘鹏 et al. 关注新型冠状病毒肺炎相关静脉血栓栓塞症的预防和诊治——《新型冠状病毒肺炎相关静脉血栓栓塞症防治建议(试行)》解读[J]. 中华普通外科杂志, 2020, 35 (3): 259- 262
GAO Qian , ZHEN Kaiyuan , LIU Peng et al. Focus on the prevention and treatment of venous thromboembolism related to COVID-19-interpretation of recommendations for prevention and treatment of COVID-19-related venous thromboembolism (trial)[J]. Chinese Journal of General Surgery, 2020, 35 (3): 259- 262
doi: 10.3760/cma.j.cn113855-20200220-00101
[1] HE Yeyan,ZHENG Chanying. Replication and transmission mechanisms of highly pathogenic human coronavirus[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 324-339.
[2] LUN Yongzhi,LIU Ben,DONG Wen,SUN Jie,PAN Linghong. Comparative analysis of structural characteristics and epitopes in S proteins between SARS-CoV-2 and SARS-CoV[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 315-323.
[3] HU Yan, LI Xiaofeng, GONG Weiyue. Nutritional support for critically ill patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 347-355.
[4] WANG Jincheng,LIU Jinpeng,WANG Yuanyuan,LIU Wei,CHEN Xiaoqun,SUN Chao,SHEN Xiaoyong,WANG Qidong,WU Yaping,LIANG Wenjie,RUAN Lingxiang. Dynamic changes of chest CT imaging in patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 191-197.
[5] ZHANG Xiaoyan, SUN Wei, SHANG Shiqiang, MAO Jianhua, FU Junfen, SHU Qiang, JIANG Kewen. Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 170-177.
[6] CAO Shengli,FENG Peihua,SHI Pengpeng. Study on the epidemic development of COVID-19 in Hubei province by a modified SEIR model[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 178-184.
[7] CHEN Jun,LIU Danping,LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING Yun,HUANG Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 215-219.
[8] CHEN Zhimin,FU Junfen,SHU Qiang,WANG Wei,CHEN Yinghu,HUA Chunzhen,LI Fubang,LIN Ru,TANG Lanfang,WANG Tianlin,WANG Yingshuo,XU Weize,YANG Zihao,YE Sheng,YUAN Tianming,ZHANG Chenmei,ZHANG Yuanyuan. Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition)[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 139-146.
[9] XU Kaijin,CAI Hongliu,SHEN Yihong,NI Qin,CHEN Yu,HU Shaohua,LI Jianping,WANG Huafen,YU Liang,HUANG He,QIU Yunqing,WEI Guoqing,FANG Qiang,ZHOU Jianying,SHENG Jifang,LIANG Tingbo,LI Lanjuan. Management of COVID-19: the Zhejiang experience[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 147-157.
[10] JIANG Saiping,LI Lu,RU Renping,ZHANG Chunhong,RAO Yuefeng,LIN Bin,WANG Rongrong,CHEN Na,WANG Xiaojuan,CAI Hongliu,SHENG Jifang,ZHOU Jianying,LU Xiaoyang,QIU Yunqing. Pharmaceutical care for severe and critically ill patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 158-169.
[11] LI Xin,DAI Tian,WANG Hong,SHI Junnian,YUAN Wei,LI Jing,CHEN Lijun,ZHANG Tianming,ZHANG Shanshan,KONG Yan,YUE Ning,SHI Hui,HE Yuping,HU Huifang,LIU Furong,YANG Caixia. Clinical analysis of suspected COVID-19 patients with anxiety and depression[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 203-208.
[12] LUO Song,YANG Lijuan,WANG Chun,LIU Chuanmiao,LI Dianming. Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 227-231.
[13] HONG Dongsheng,NI Jian,SHAN Wenya,LI Lu,HU Xi,YANG Hongyu,ZHAO Qingwei,ZHANG Xingguo. Establishment of a rapid identification of adverse drug reaction program in R language implementation based on monitoring data[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 253-259.
[14] ZHONG Qi,LI Zhi,SHEN Xiaoyong,XU Kaijin,SHEN Yihong,FANG Qiang,CHEN Feng,LIANG Tingbo. CT imaging features of patients with different clinical types of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 198-202.
[15] KANG Xianhui,ZHANG Rong,HE Huiliang,YAO Yongxing,ZHENG Yueying,WEN Xiaohong,ZHU Shengmei. Anesthesia management in cesarean section for patient with COVID-19: a case report[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 249-252.